Acquisition of extensive drug-resistant Pseudomonas aeruginosa among hospitalized patients: Risk factors and resistance mechanisms to carbapenems

Journal of Hospital Infection

Volumn 79, Issue 1, 2011, Pages 54-58

  Park, Y S ^a   Lee, H ^b   Chin, B S ^c   Han, S H ^c,f   Hong, S G ^d   Hong, S K ^d   Kim, H Y ^e   Uh, Y ^e   Shin, H B ^f   Choo, E J ^f   Song, W ^g   Jeong, S H ^c   Lee, K ^c   Kim, J M ^c  

^a Gachon University College of Medicine   (South Korea)

^b Kwandong University College of Medicine   (South Korea)

^c Yonsei University College of Medicine   (South Korea)

^d CHA University   (South Korea)

^e Wonju Severance Christian Hospital   (South Korea)

^f Soonchunhyang University College of Medicine   (South Korea)

^g Hallym University   (South Korea)

Author keywords

Carbapenem resistance; Extensive drug resistance; Pseudomonas aeruginosa; Risk factor

Indexed keywords

AMIKACIN; AMINOGLYCOSIDE; AZTREONAM; BETA LACTAMASE INHIBITOR; CARBAPENEM; CEFEPIME; CEFTAZIDIME; CEPHALOSPORIN; CIPROFLOXACIN; COLISTIN; GENTAMICIN; GLYCOPEPTIDE; IMIPENEM; MEROPENEM; METALLO BETA LACTAMASE; PENICILLIN G; PIPERACILLIN; PIPERACILLIN PLUS TAZOBACTAM; QUINOLONE;

ADULT; AGED; APACHE; ARTICLE; ARTIFICIAL VENTILATION; BACTERIUM ISOLATE; CASE CONTROL STUDY; CENTRAL VENOUS CATHETER; COMORBIDITY; DIABETES MELLITUS; DISEASE SEVERITY; FEMALE; GENE SEQUENCE; HEART DISEASE; HOSPITAL PATIENT; HOSPITALIZATION; HUMAN; INTENSIVE CARE UNIT; KIDNEY DISEASE; KOREA; LUNG DISEASE; MALE; MINIMUM INHIBITORY CONCENTRATION; NASOGASTRIC TUBE; NEOPLASM; NEUROLOGIC DISEASE; POLYMERASE CHAIN REACTION; PSEUDOMONAS; PSEUDOMONAS INFECTION; PULSED FIELD GEL ELECTROPHORESIS; RISK FACTOR; SEPTIC SHOCK; TERTIARY HEALTH CARE; URINARY CATHETER;

AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; BETA-LACTAMASES; CARBAPENEMS; CASE-CONTROL STUDIES; DRUG RESISTANCE, MULTIPLE, BACTERIAL; FEMALE; HOSPITALS; HUMANS; MALE; MIDDLE AGED; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; REPUBLIC OF KOREA; RESPIRATION, ARTIFICIAL; RISK FACTORS; SEVERITY OF ILLNESS INDEX;

EID: 80051471695     PISSN: 01956701     EISSN: 15322939     Source Type: Journal    
DOI: 10.1016/j.jhin.2011.05.014     Document Type: Article

References (28)

1. Gaynes R., Edwards J.R. Overview of nosocomial infections caused by Gram-negative bacilli. Clin Infect Dis 2005, 41:848-854.
2. Aris R.M., Gilligan P.H., Neuringer I.P., Gott K.K., Rea J., Yankaskas J.R. The effects of panresistant bacteria in cystic fibrosis patients on lung transplant outcome. Am J Respir Crit Care Med 1997, 155:1699-1704.
3. Aloush V., Navon-Venezia S., Seigman-Igra Y., Cabili S., Carmeli Y. Multidrug-resistant Pseudomonas aeruginosa: risk factors and clinical impact. Antimicrob Agents Chemother 2006, 50:43-48.
4. Giske C.G., Monnet D.L., Cars O., Carmeli Y. Clinical and economic impact of common multidrug-resistant Gram-negative bacilli. Antimicrob Agents Chemother 2008, 52:813-821.
5. Paterson D.L. The epidemiological profile of infections with multidrug-resistant Pseudomonas aeruginosa and Acinetobacter species. Clin Infect Dis 2006, 43(Suppl. 2):S43-S48.
6. Falagas M.E., Karageorgopoulos D.E. Pandrug resistance (PDR), extensive drug resistance (XDR), and multidrug resistance (MDR) among Gram-negative bacilli: need for international harmonization in terminology. Clin Infect Dis 2008, 46:1121-1122. author reply 1122.
7. Harris A.D., Karchmer T.B., Carmeli Y., Samore M.H. Methodological principles of case-control studies that analyzed risk factors for antibiotic resistance: a systematic review. Clin Infect Dis 2001, 32:1055-1061.
8. Harris A.D., Samore M.H., Lipsitch M., Kaye K.S., Perencevich E., Carmeli Y. Control-group selection importance in studies of antimicrobial resistance: examples applied to Pseudomonas aeruginosa, Enterococci, and. Escherichia coli. Clin Infect Dis 2002, 34:1558-1563.
9. Kaye K.S., Harris A.D., Samore M., Carmeli Y. The case-case-control study design: addressing the limitations of risk factor studies for antimicrobial resistance. Infect Control Hosp Epidemiol 2005, 26:346-351.
10. Performance standards for antimicrobial susceptibility testing; seventeenth informational supplement. M100-S17 2007, Clinical and Laboratory Standard Institute, CLSI, Wayne, PA.
11. Charlson M.E., Pompei P., Ales K.L., MacKenzie C.R. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chron Dis 1987, 40:373-383.
12. Lee K., Chong Y., Shin H.B., Kim Y.A., Yong D., Yum J.H. Modified Hodge and EDTA-disk synergy tests to screen metallo-beta-lactamase-producing strains of Pseudomonas and Acinetobacter species. Clin Microbiol Infect 2001, 7:88-91.
13. Lee K., Yum J.H., Yong D., et al. Novel acquired metallo-beta-lactamase gene, bla(SIM-1), in a class 1 integron from Acinetobacter baumannii clinical isolates from Korea. Antimicrob Agents Chemother 2005, 49:4485-4491.
14. Lee K., Lim J.B., Yum J.H., et al. bla(VIM-2) cassette-containing novel integrons in metallo-beta-lactamase-producing Pseudomonas aeruginosa and Pseudomonas putida isolates disseminated in a Korean hospital. Antimicrob Agents Chemother 2002, 46:1053-1058.
15. Talbot G.H., Bradley J., Edwards J.E., Gilbert D., Scheld M., Bartlett J.G. Bad bugs need drugs: an update on the development pipeline from the antimicrobial availability task force of the infectious diseases society of America. Clin Infect Dis 2006, 42:657-668.
16. Falagas M.E., Bliziotis I.A., Kasiakou S.K., Samonis G., Athanassopoulou P., Michalopoulos A. Outcome of infections due to pandrug-resistant (PDR) Gram-negative bacteria. BMC Infect Dis 2005, 5:24.
17. Tam V.H., Chang K.T., LaRocco M.T., et al. Prevalence, mechanisms, and risk factors of carbapenem resistance in bloodstream isolates of Pseudomonas aeruginosa. Diagn Microbiol Infect Dis 2007, 58:309-314.
18. Fortaleza C.M., Freire M.P., Filho Dde C., de Carvalho Ramos M. Risk factors for recovery of imipenem- or ceftazidime-resistant Pseudomonas aeruginosa among patients admitted to a teaching hospital in Brazil. Infect Control Hosp Epidemiol 2006, 27:901-906.
19. Ozkurt Z., Ertek M., Erol S., Altoparlak U., Akcay M.N. The risk factors for acquisition of imipenem-resistant Pseudomonas aeruginosa in the burn unit. Burns 2005, 31:870-873.
20. Zavascki A.P., Cruz R.P., Goldani L.Z. Risk factors for imipenem-resistant Pseudomonas aeruginosa: a comparative analysis of two case-control studies in hospitalized patients. J Hosp Infect 2005, 59:96-101.
21. Harris A.D., Smith D., Johnson J.A., Bradham D.D., Roghmann M.C. Risk factors for imipenem-resistant Pseudomonas aeruginosa among hospitalized patients. Clin Infect Dis 2002, 34:340-345.
22. Wang C.Y., Jerng J.S., Chen K.Y., et al. Pandrug-resistant Pseudomonas aeruginosa among hospitalised patients: clinical features, risk factors and outcomes. Clin Microbiol Infect 2006, 12:63-68.
23. Ferreira A.C., Gobara S., Costa S.E., et al. Emergence of resistance in Pseudomonas aeruginosa and Acinetobacter species after the use of antimicrobials for burned patients. Infect Control Hosp Epidemiol 2004, 25:868-872.
24. Crespo M.P., Woodford N., Sinclair A., et al. Outbreak of carbapenem-resistant Pseudomonas aeruginosa producing VIM-8, a novel metallo-beta-lactamase, in a tertiary care center in Cali, Colombia. J Clin Microbiol 2004, 42:5094-5101.
25. Nouer S.A., Nucci M., de-Oliveira M.P., Pellegrino F.L., Moreira B.M. Risk factors for acquisition of multidrug-resistant Pseudomonas aeruginosa producing SPM metallo-beta-lactamase. Antimicrob Agents Chemother 2005, 49:3663-3667.
26. Falagas M.E., Kopterides P. Risk factors for the isolation of multi-drug-resistant Acinetobacter baumannii and Pseudomonas aeruginosa: a systematic review of the literature. J Hosp Infect 2006, 64:7-15.
27. Bonomo R.A., Szabo D. Mechanisms of multidrug resistance in Acinetobacter species and Pseudomonas aeruginosa. Clin Infect Dis 2006, 43(Suppl. 2):S49-S56.
28. Nho S.O., Jin J.S., Kim J.W., et al. Dissemination of the blaIMP-1 and blaVIM-2 metallo-beta-lactamase genes among genetically unrelated Pseudomonas aeruginosa isolates in a South Korean hospital. Int J Antimicrob Agents 2008, 31:586-588.